KRAS and acute lymphoblastic leukemia: For the Ras/MAP Kinase pathway, since the majority of the studies evaluated the impact of KRAS mutations in mouse models with T-cell neoplasia [31,32], our KRAS data provides additional information in the evaluation of frequency and prognostic impact of these mutations in the largest described series of T-ALL patients.